Therapy of cognitive disorders in chronic cerebral ischemia in general medical practice
Smetneva N.S.¹, Goloborodova I.V.¹, Popkova A.M.¹, Samoylova N.V.¹, Igonina N.P.¹, Shatrova G.V.², Panevin T.C.<sup>3

1</sup> A.I. Yevdokimov Moscow State University of Medicine and Dentistry
² City Polyclinic No. 5, Moscow
³ National medical Research Center of Endocrinology, Moscow

The problem of population aging and widespread prevalence of comorbidity with the presence of chronic cerebral ischemia (CCI) requires a multidisciplinary approach, involving physicians, general practitioners and neurologists. CCI is one of the most common diseases leading to a serious decrease in the quality of life and severe disability of older patients. The article presents data on the etiology, diagnostic possibilities and basic principles of CCI therapy. Treatment of CCI, accompanied by cognitive disorders, includes the treatment of the underlying disease, non-drug therapy and the use of neuroprotective drugs. Among the drugs with neuroprotective properties, Actovegin is a unique preparation of biological origin that can provide multiple effects on both microcirculation and cellular metabolic processes and the regulation of neuronal apoptosis, and ultimately improve the cognitive function of patients with cerebral vascular diseases. This drug has an extensive evidence base in both experimental and clinical trials. Due to its low influence on blood pressure and a high safety profile, Actovegin can be recommended for a wide use in the therapy of patients with CCI.

Key words: chronic cerebral ischemia, dyscirculatory encephalopathy, dementia, cognitive disorders, neuroprotective drugs, Actovegin.
For citation: Smetneva N.S., Goloborodova I.V., Popkova A.M. et al. Therapy of cognitive disorders in chronic cerebral ischemia in general medical practice // RMJ. 2018. № 7. P. 15–22.